CALIFORNIA: Patients who consume plant-derived cannabis extracts in the form of an oral lozenge report reductions in chronic pain and opioid use, according to clinical data published in the journal Frontiers in Neuroscience.
Investigators from the United States, the Netherlands, and Spain assessed the safety and efficacy of the Trokie brand lozenge in a cohort of medical cannabis patients in California. The lozenges contained standardized quantities of THC and/or CBD.
Researchers reported: “[T]he use of Trokie lozenges is associated with a self-reported pain reduction in chronic, non-cancer pain patients. … [T]he proportion of participants reducing or discontinuing opiate analgesics was … 84 percent, similar to what has been previously found in a study based on patient self-reports. … [T]he findings support the need for conducting a phase 1 clinical trial to formally characterize the pharmacokinetic profile of Trokie® lozenges in humans.”
Several prior studies have similarly reported that chronic pain patients enrolled in state-sponsored medical cannabis access programs reduce or eliminate their use of opioids over time.
For more information, contact Paul Armentano, NORML Deputy Director, at: firstname.lastname@example.org. Full text of the study, “Self-reported effectiveness and safety of Trokie® lozenges: A standardized formulation for the buccal delivery of cannabis extracts,” appears in Frontiers in Neuroscience. NORML’s fact-sheet highlighting the relevant, peer-reviewed research specific to the relationship between cannabis and opioids is available online.